Effectiveness of IDegLira in Type-2 Diabetes Patients During the COVID-19 Pandemic: A Teleconsultation Follow-up

Gustavo Adolfo Parra Serrano, Maria Paula Torres Langhammer, Andrea Juliana Pinto Arias, Sergio Eduardo Serrano Gomez

Research output: Articles / NotesScientific Articlepeer-review

Abstract

Introduction: The current management of type 2 diabetes mellitus (T2D) requires a
comprehensive approach to achieve goals, emphasizing treatment compliance through
periodic surveillance.
Objective: The purpose of this study was to determine the effectiveness of insulin degludec/
liraglutide therapy (IDegLira) on glycemic control in adults with T2D in a real-world setting,
with follow-up care provided via teleconsultation during the COVID-19 pandemic.
Materials and methods: Analysis of a real-world anonymized database of patients with
T2D, treated in a specialized medical institution between March 2020 and March 2021.
HbA1c levels and fasting blood glucose were evaluated at three and six months of followup.
Results: We included 61 patients between the age of 43 and 94 years. Most of the patients
used oral antidiabetics (75.41%), 85.25% had insulin formulations (basal or basal-bolus),
and half of the subjects (55.74%) had insulin-combined formulations. From an average
level of HbA1c at baseline of 8.44% (SD 1.4), significant reductions were observed at three
months (-0.48%, CI -0.10 to -0.86) and six months-(0.94%, CI -0.55 to -1.33), consistent
with a decrease in fasting glycemia (-37.80 mg/dL, CI -21.62 to -53.97 at six months) and
with an increase in the proportion of patients achieving glycemic goals. Insulin requirements
(total daily dose) decreased on average 11.3 U (CI -6.59 to -16.01, p 0.00). No episodes
of significant hypoglycemia were reported.
Conclusions: In the real world, IDegLira generated significant changes towards glycemic
control in adults with T2D, with no reports of hypoglycemia for up to 6 months in the
context of virtual medical care
Original languageSpanish (Colombia)
Pages (from-to)511-520
JournalRevista Colombiana De Endocrinologia Diabetes Metabolismo
Volume9
Issue number4
DOIs
StatePublished - 19 Oct 2022

Cite this